Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice

被引:72
作者
Bradbury, MJ
Campbell, U
Giracello, D
Chapman, D
King, C
Tehrani, L
Cosford, NDP
Anderson, J
Varney, MA
Strack, AM
机构
[1] Merck Res Labs, Dept Pharmacol, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Neuropharmacol, San Diego, CA USA
[3] Merck Res Labs, Dept Chem, San Diego, CA USA
关键词
D O I
10.1124/jpet.104.076406
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The metabotropic glutamate receptor subtype mGlu5 modulates central reward pathways. Many transmitter systems within reward pathways affect feeding. We examined the potential role of mGlu5 in body weight regulation using genetic and pharmacological approaches. Adult mice lacking mGlu5, mGluR5(-/-), weighed significantly less than littermate controls (mGluR5(+/+)), despite no difference in ad libitum food intake. After overnight food deprivation, mGluR5(-/-) mice ate significantly less than their mGluR5(+/+) controls when refeeding. When on a high fat diet, mGluR5(-/-) mice weighed less and had decreased plasma insulin and leptin concentrations. The selective mGlu5 antagonist MTEP [3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine; 15 mg/kg s.c.] reduced refeeding after overnight food deprivation in mGluR5(+/+), but not mGluR5(-/-) mice, demonstrating that feeding suppression is mediated via a mGlu5 mechanism. MTEP (1-10 mg/kg) decreased night-time food intake in rats in a dose-related manner. At 10 mg/kg, MTEP injected at 8.5, 4.5, or 0.5 h before refeeding reduced overnight food intake by approximately similar to 30%. Diet-induced obese (DIO) and age-matched lean rats were treated for 12 days with MTEP (3 or 10 mg/kg/day s.c.), dexfenfluramine (3 mg/kg/ day s.c.), or vehicle. Daily and cumulative food intakes were reduced in DIO rats by MTEP and dexfenfluramine. Weight gain was prevented with MTEP (3 mg/kg), and weight and adiposity loss was seen with MTEP (10 mg/kg) and dexfenfluramine. Caloric efficiency was decreased, suggesting increased energy expenditure. In lean rats, similar, although smaller, effects were observed. In conclusion, using genetic and pharmacological approaches, we have shown that mGlu5 modulates food intake and energy balance in rodents.
引用
收藏
页码:395 / 402
页数:8
相关论文
共 38 条
[1]   In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine) [J].
Anderson, JJ ;
Bradbury, MJ ;
Giracello, DR ;
Chapman, DF ;
Holtz, G ;
Roppe, J ;
King, C ;
Cosford, NDP ;
Varney, MA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 473 (01) :35-40
[2]   [3H]methoxymethyl-3-[(2-methylyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain:: In vitro and in vivo characterization [J].
Anderson, JJ ;
Rao, SP ;
Rowe, B ;
Giracello, DR ;
Holtz, G ;
Chapman, DF ;
Tehrani, L ;
Bradbury, MJ ;
Cosford, NDP ;
Varney, MA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) :1044-1051
[3]   Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors [J].
Arnone, M ;
Maruani, J ;
Chaperon, F ;
Thiebot, MH ;
Poncelet, M ;
Soubrie, P ;
LeFur, G .
PSYCHOPHARMACOLOGY, 1997, 132 (01) :104-106
[4]   mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior [J].
Bäckström, P ;
Bachteler, D ;
Koch, S ;
Hyytiä, P ;
Spanagel, R .
NEUROPSYCHOPHARMACOLOGY, 2004, 29 (05) :921-928
[5]   Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic-pituitary-adrenal axis activity: interaction with serotonergic systems [J].
Bradbury, MJ ;
Giracello, DR ;
Chapman, DF ;
Holtz, G ;
Schaffhauser, H ;
Rao, SP ;
Varney, MA ;
Anderson, JJ .
NEUROPHARMACOLOGY, 2003, 44 (05) :562-572
[6]   The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine, (MTEP) in rodent models of anxiety [J].
Busse, CS ;
Brodkin, J ;
Tattersall, D ;
Anderson, JJ ;
Warren, N ;
Tehrani, L ;
Bristow, LJ ;
Varney, MA ;
Cosford, NDP .
NEUROPSYCHOPHARMACOLOGY, 2004, 29 (11) :1971-1979
[7]   Effects of obesity on pharmacokinetics - Implications for drug therapy [J].
Cheymol, G .
CLINICAL PHARMACOKINETICS, 2000, 39 (03) :215-231
[8]   Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice [J].
Chiamulera, C ;
Epping-Jordan, MP ;
Zocchi, A ;
Marcon, C ;
Cottiny, C ;
Tacconi, S ;
Corsi, M ;
Orzi, F ;
Conquet, F .
NATURE NEUROSCIENCE, 2001, 4 (09) :873-874
[9]   Increased dietary fat attenuates the anorexic effects of intracerebroventricular injections of MTII [J].
Clegg, DJ ;
Benoit, SC ;
Air, EL ;
Jackman, A ;
Tso, P ;
D'Alessio, D ;
Woods, SC ;
Seeley, RJ .
ENDOCRINOLOGY, 2003, 144 (07) :2941-2946
[10]   SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats [J].
Cohen, C ;
Perrault, G ;
Voltz, C ;
Steinberg, R ;
Soubrié, P .
BEHAVIOURAL PHARMACOLOGY, 2002, 13 (5-6) :451-463